脂代谢与动脉粥样硬化PPT.pptVIP

脂代谢与动脉粥样硬化;Elevated Cholesterol Is a Risk Factor for CVD;;人类胆固醇净平衡;INHIBITION OF CHOLESTEROL SYNTHESIS RESULTS IN A HIGHER ABSORPTION RATE OF CHOLESTEROL FROM THE INTESTINE*;肠道内胆固醇吸收;Uptake of a fluorescent cholesterol analog in hamster small intestine;PNAS 102, 8132, 2005;肠道胆固醇吸收被依折麦布抑制了54% (p 0.001);依折麦布：降低致粥样硬化脂蛋白中的胆固醇含量;依折麦布：降低致粥样硬化脂蛋白中的胆固醇含量;依折麦布：降低致粥样硬化脂蛋白中的胆固醇含量;;;依折麦布（益适纯? ）与他汀类联合给药的原理;益适纯?与他汀类联合用药: 研究结果的一致性;*p0.01 益适纯? +汇总的他汀类剂量与单用汇总的他汀类剂量比较; **p=0.03益适纯? +汇总的他汀类剂量与单用汇总的他汀类剂量比较 摘自Ballantyne CM et al Circulation 2003;107:2409-2415; Davidson MH et al J Am Coll Cardiol 2002;40:2125-2134; Melani L et al Eur Heart J 2003;24:717-728; Kerzner B et al Am J Cardiol 2003;91:418-424.;*中位变化; **p0.01 益适纯? +汇总的他汀类剂量与单用汇总的他汀类剂量比较 摘自Ballantyne CM et al Circulation 2003;107:2409-2415; Davidson MH et al J Am Coll Cardiol 2002;40:2125-2134; Melani L et al Eur Heart J 2003;24:717-728; Kerzner B et al Am J Cardiol 2003;91:418-424.;;Third Joint Task Force Guidelines for CVD Prevention: Lipid Management;Goals for Management of Hyperlipidemia in Patients With Diabetes ;病人*LDL-C总体NCEP ATP III达标％ 和根据NCEP 危险分层的达标％;依折麦布联合他汀治疗良好的安全性-汇总结果4个多中心、随机、双盲、安慰剂对照研究，共入组2382个病人，包括依折麦布和阿托伐他汀、辛伐他汀、普伐他汀和洛伐他汀所有剂量的联合治疗;*都无症状，继续或停用药物后可逆。 ULN=正常值上限; ALT=alanine aminotransferase; AST=aspartate aminotransferase; GGT=gamma-glutamyl transpeptidase; CPK=creatine phosphokinase Adapted from Data from Registration File, MSP.;REVERSALThe Need for Intensive LDL-C Lowering: Relationship Between Degree of LDL-C Reduction and Change in Atheroma Volume;Simvastatin With or Without Ezetimibe in Familial Hypercholesterolemia;Background;ENHANCE Study Design;Months;Other Lipids and Apolipoproteins;hsCRP;Mean cIMT during 24 months of therapyLongitudinal, repeated measures analysis;Conclusion;脂质代谢机制;依折麦布与他汀类联合应用：总结